drugset / Trial / NCT06629259
Guanfacine for Alcohol Use Disorder (AUD)
Phase 2
Recruiting
200 enrolled
Indiana University
National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The investigators assess whether guanfacine extended release (GXR; 3mg/d) compared with placebo (PBO) will attenuate drinking and drinking-related factors in N=200 men and women with Alcohol Use Disorder (AUD) across 12-weeks.
Timeline
- Start
- 2025-10-03
- Primary completion
- 2029-08-31
- Completion
- 2029-09-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Guanfacine | Small molecule | 3 mg | Oral |